Exicure’s science may be complicated to the lay person but their successes are easy to admire. Way to go to the great leadership team and researchers at Exicure for witnessing your success as a company warrant being listed on the Russell 3000R index. Your investors are excited about your accomplishments from a financial as well as a scientific stand point.
Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure’s proprietary spherical nucleic acid (SNA™) architecture is designed to unlock the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure’s lead programs address inflammatory diseases, genetic disorders and oncology.”
